A Case of Pseudoprogression During Atezolizumab Therapy 
in Lung Adenocarcinoma

A Case of Pseudoprogression During Atezolizumab Therapy 
in Lung Adenocarcinoma

Lung cancer is the most common cause of cancer-related death worldwide. There are two classes of lung cancer: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC represents approximately 85% of all lung cancer cases. Immune checkpoint inhibitors (ICIPs) are a class of inhibit...

Full description

Bibliographic Details
Main Authors: Xue WANG, Yi ZHAO, Zhiwei CHEN
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2019-06-01
Series:Chinese Journal of Lung Cancer
Subjects:
NSCLC
Immunotherapy
PD-L1
Atezolizumab
Pseudoprogression
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2019.06.10

Internet

http://dx.doi.org/10.3779/j.issn.1009-3419.2019.06.10

Similar Items